Statin use and clinical outcomes in hospitalized COVID-19 patients: A retrospective analysis in Riyadh, Saudi Arabia
Khalid S Alshaalan1, Rahaf F Alkahtani1, Renad F Althobaiti1
1From the Department of Dermatology (Alshaalan); from the Department of Family Medicine (Alahmadi); from the Department of Internal Medicine and Adult Infectious Diseases (Rebh); from the Department of of Intensive Care Unit (Alshabanah), Prince Mohammad Bin Abdul-Aziz Hospital, from the College of Medicine (Alkahtani, Althobaiti, Aldhahi, Algezlan, M. Alanazi, Alrumaih, Alturki, A. Alanazi), Al Imam Muhammad Ibn Saud Islamic University, and from the Department of Internal Medicine and Infectious Diseases (Al Ali), King Saud Medical City, Riyadh, Kingdom of Saudi Arabia.
Insights
This study found that statin use in hospitalized COVID-19 patients significantly increased the risk of intensive care unit admission, intubation, complications, and mortality. These findings highlight potential adverse effects of statins in severe coronavirus disease-19 cases.
Area of Science:
- Cardiology
- Infectious Diseases
- Clinical Research
Background:
- Statins are widely prescribed lipid-lowering medications.
- The impact of statin use on coronavirus disease-19 (COVID-19) severity remains under investigation.
- Understanding this relationship is crucial for managing patients with COVID-19 and cardiovascular risk factors.
Purpose of the Study:
- To examine the association between statin use and the severity of COVID-19.
- To determine if statin therapy influences outcomes in hospitalized COVID-19 patients.
Main Methods:
- Retrospective study design.
- Inclusion of adult patients hospitalized with confirmed COVID-19 at Prince Mohammed Bin Abdulaziz Hospital, Riyadh, Saudi Arabia (July-September 2020).
- Evaluation of antecedent statin use via electronic medical records.
Main Results:
- Data from 689 COVID-19 patients were analyzed.
- Statin use was associated with a 1.64-fold increased risk of ICU admission.
- Statin use significantly elevated risks for intubation (1.76-fold), complications (2.48-fold), and mortality (3.16-fold).
Conclusions:
- Statin use is linked to increased morbidity and mortality in hospitalized COVID-19 patients.
- Findings suggest a potential detrimental effect of statins on COVID-19 outcomes.
- Further research is warranted to elucidate the mechanisms behind this association.
Objectives:
To investigate the relationship between statin use and coronavirus disease-19 (COVID-19) severity.
Methods:
This was a retrospective study of adult patients with confirmed COVID-19 who were hospitalized at Prince Mohammed Bin Abdulaziz Hospital, Riyadh, Saudi Arabia. The study was carried out from July - September 2020. Antecedent statin use was evaluated using medication information available in the electronic medical records.
Results:
In this retrospective study, we collected data from 689 patients hospitalized with COVID-19. Among the patients, 56.2% of them were non-Saudi and 67.3% were males. The mean age of the patients was 53.7 years. The most common comorbidities among patients with COVID-19 at admission were hypertension (65.2%) and diabetes mellitus (65%). Among these patients, 155 (22.5%) patients received statins during hospitalization and 79.7% of them received corticosteroids. Receiving statins significantly increased the risk of intensive care unit's admission by 1.64 times, intubation by 1.76 times, developing complications by 2.48 times, and mortality by 3.16 times.
Conclusion:
Statins are associated with a higher risk of mortality and morbidity among patients hospitalized for COVID-19.
More Related Videos
Related Concept Videos
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:25Antihypertensive Drugs: Direct Renin Inhibitors